Wilson celebrates the first U.S. patient to complete gene therapy for sickle cell, but says advocacy must continue.
Hosted on MSN16m
Here are 4 biotech stocks that could get a boost from a more open FDA regulatory climateSkorney cited a drug called Oxbryta from Pfizer which was approved to treat the blood disorder sickle cell. Instead of using ...
It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after an agreement was reached ...
It may be possible to collect nearly three times as many stem cells for sickle cell gene therapy with motixafortide than standard plerixafor.
When Pfizer acquired Global Blood Therapeutics in October 2022, the flagship drug in the company’s portfolio was Oxbryta, a groundbreaking treatment that targets the root cause of sickle cell ...
The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...
Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...
The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of using decades-old transplant drugs alongside cutting-edge CRISPR medicines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback